Method of treating prostatic adenocarcinoma
April 5, 2011. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.Patent ReferencesPhosphonic acid substituted aromatic steroids as inhibitors of steroid 5--reductase Steroid 5-alpha-reductase inhibitors Phosphinic acid substituted aromatic steroids as inhibitors of steroid 5-60 -reductase Phosphonic acid substituted steroids as steroid 5-reductase inhibitors Sulfonic acid substituted aromatic steroids as inhibitors of steroid 5--reductase Steriod 5-alpha-reductase inhibitors 7-keto or hydroxy 3,5-diene steroids as inhibitors of steroid 5-alpha reductase 11-keto or hydroxy 3,5-diene steroids as inhibitors of steriod 5--reductase Steroidal 3-acetic acid derivatives as 5-alpha-reductase inhibitors Patent #: 5137882 InventorAssigneeApplicationNo. 544709 filed on 06/27/1990US Classes:424/423, Surgical implant or material424/451, Capsules (e.g., of gelatin, of chocolate, etc.)424/456, Gelatin424/464, Tablets, lozenges, or pills514/169, Cyclopentanohydrophenanthrene ring system DOAI514/172, Hetero ring containing514/173, Spiro ring system514/177, Oxygen double bonded to a ring carbon of the cyclopentanohydrophenanthrene ring system514/178, Oxygen single bonded to a ring carbon of the cyclopentanohydrophenanthrene ring system514/182, Oxygen single bonded to a ring carbon of the cyclopentanohydrophenanthrene ring system514/319, The additional ring is one of the cyclos in a polycyclo ring system514/428, Chalcogen bonded indirectly to the five-membered hetero ring by acyclic nonionic bonding514/462, Spiro ring system514/510, Polycyclo ring system514/573Cyclopentyl or cyclopentene (e.g., prostaglandins, etc.)ExaminersPrimary: Page, Thurman K.Assistant: Azpuru, C. Attorney, Agent or FirmForeign Patent References
International ClassesA61K 009/20A61K 009/48 A61K 031/56 A61K 031/58 AbstractInvented is a Method of Treating Prostatic Adenocarcinoma by employing a steroid 5--reductase inhibiting compound or a combination of steroid 5--reductase inhibiting compounds.Other References
Field of SearchCyclopentanohydrophenanthrene ring system DOAIHetero ring containing Spiro ring system Oxygen double bonded to a ring carbon of the cyclopentanohydrophenanthrene ring system Oxygen single bonded to a ring carbon of the cyclopentanohydrophenanthrene ring system Oxygen single bonded to a ring carbon of the cyclopentanohydrophenanthrene ring system The additional ring is one of the cyclos in a polycyclo ring system Chalcogen bonded indirectly to the five-membered hetero ring by acyclic nonionic bonding Spiro ring system Polycyclo ring system Cyclopentyl or cyclopentene (e.g., prostaglandins, etc.) Surgical implant or material Capsules (e.g., of gelatin, of chocolate, etc.) Gelatin Tablets, lozenges, or pills | |
